Verrica Pharmaceuticals I... (VRCA)
Verrica Pharmaceuticals Statistics
Share Statistics
Verrica Pharmaceuticals has 91.78M shares outstanding. The number of shares has increased by 116.36% in one year.
| Shares Outstanding | 91.78M |
| Shares Change (YoY) | 116.36% |
| Shares Change (QoQ) | 1.34% |
| Owned by Institutions (%) | 63.94% |
| Shares Floating | 49.69M |
| Failed to Deliver (FTD) Shares | 6.84K |
| FTD / Avg. Volume | 1.71% |
Short Selling Information
The latest short interest is 2.85M, so 3.1% of the outstanding shares have been sold short.
| Short Interest | 2.85M |
| Short % of Shares Out | 3.1% |
| Short % of Float | 4.18% |
| Short Ratio (days to cover) | 4.24 |
Valuation Ratios
The PE ratio is -0.47 and the forward PE ratio is -1.68. Verrica Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.47 |
| Forward PE | -1.68 |
| PS Ratio | 4.79 |
| Forward PS | 0.3 |
| PB Ratio | -3.68 |
| P/FCF Ratio | -0.59 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verrica Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of -4.66.
| Current Ratio | 1.76 |
| Quick Ratio | 1.68 |
| Debt / Equity | -4.66 |
| Debt / EBITDA | -0.7 |
| Debt / FCF | -0.75 |
| Interest Coverage | -7 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $106.56K |
| Profits Per Employee | $-1.08M |
| Employee Count | 71 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.75 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -92.93% in the last 52 weeks. The beta is 1.68, so Verrica Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.68 |
| 52-Week Price Change | -92.93% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 44.95 |
| Average Volume (20 Days) | 400.93K |
Income Statement
In the last 12 months, Verrica Pharmaceuticals had revenue of 7.57M and earned -76.58M in profits. Earnings per share was -1.48.
| Revenue | 7.57M |
| Gross Profit | 5.71M |
| Operating Income | -65.92M |
| Net Income | -76.58M |
| EBITDA | -65.9M |
| EBIT | -67.17M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
The company has 46.33M in cash and 45.94M in debt, giving a net cash position of 390K.
| Cash & Cash Equivalents | 46.33M |
| Total Debt | 45.94M |
| Net Cash | 390K |
| Retained Earnings | -307.03M |
| Total Assets | 54.13M |
| Working Capital | 22.17M |
Cash Flow
In the last 12 months, operating cash flow was -60.93M and capital expenditures -27K, giving a free cash flow of -60.95M.
| Operating Cash Flow | -60.93M |
| Capital Expenditures | -27K |
| Free Cash Flow | -60.95M |
| FCF Per Share | -1.18 |
Margins
Gross margin is 75.51%, with operating and profit margins of -871.25% and -1012.15%.
| Gross Margin | 75.51% |
| Operating Margin | -871.25% |
| Pretax Margin | -1012.15% |
| Profit Margin | -1012.15% |
| EBITDA Margin | -870.98% |
| EBIT Margin | -871.25% |
| FCF Margin | -805.63% |
Dividends & Yields
VRCA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VRCA is $6, which is 1176.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $6 |
| Price Target Difference | 1176.6% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -11 |
| Piotroski F-Score | 3 |